MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
2.945
-0.015
-0.51%
Opening 10:31 05/21 EDT
OPEN
2.920
PREV CLOSE
2.960
HIGH
2.990
LOW
2.882
VOLUME
2.70M
TURNOVER
--
52 WEEK HIGH
7.18
52 WEEK LOW
2.770
MARKET CAP
1.56B
P/E (TTM)
-2.4458
1D
5D
1M
3M
1Y
5Y
1D
Can Altitude Lab’s Early Wins Reframe Recursion Pharmaceuticals’ (RXRX) High-Burn Platform Bet?
Simply Wall St · 1d ago
Weekly Report: what happened at RXRX last week (0511-0515)?
Weekly Report · 3d ago
Private Markets: $2.1B for Isomorphic Labs, massive raise looming for Anthropic
TipRanks · 6d ago
Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 05/14 17:34
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5
Benzinga · 05/14 17:23
Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley
TipRanks · 05/14 16:25
Recursion Pharmaceuticals (RXRX) Receives a Hold from Bank of America Securities
TipRanks · 05/13 10:45
Why Recursion Pharmaceuticals (RXRX) Is Down 7.4% After Founder Exit And Deepening FDA Talks
Simply Wall St · 05/12 07:32
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.